Natco Pharma, one of the few Indian companies to venture into new drug discovery research, announced that it has transferred the Lenalidomide Capsules ANDA (2.5mg, 5mg, 10mg, 15mg, 20mg and 25mg strengths) to Arrow International as per an earlier agreement between the parties.

This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties.

Arrow International (an affiliate of Teva Pharmaceutical Industries) is the marketing partner of NATCO for this product in the US market. The ANDA was approved by USFDA in May 2021 with final approval in the 5mg, 10mg, 15mg, and 25mg strengths, and tentative approval in the 2.5mg and 20mg strengths.

Shares of the company declined Rs 12.90, or 1.27%, to settle  at  Rs 1,001.70.  The total volume of shares traded  was 10,650 at  the BSE (Thursday).